Four eye health stakeholder groups have come together to help define the focus of research in age-related macular degeneration (AMD). Their purpose was to prioritize clinical questions important for researchers to answer when developing clinical practice guidelines and identifying treatment outcomes important to patients. Participants in the initiative were: American Academy of Ophthalmology (AAO) Retina/Vitreous [Read More]
Category: Research and Developments
Mifepristone Still Showing Positive Results for Treatment of Central Serous Chorioretinopathy
For the past 18 years, reports have been published here on the slow progress of research for treatment of central serous chorioretinopathy (CSC). Sometimes misdiagnosed as early-onset age-related macular degeneration, CSC is a disease of the central retina (the macula) affecting mostly middle-aged males, and it is thought to be caused by over-production of stress [Read More]
New Port Delivery System Unveiled for Wet AMD Treatment
Genentech has announced positive, top line results from a Phase 2 study of its Port Delivery System (PDS) with Lucentis in people with wet age-related macular degeneration (AMD). The small, refillable eye implant, which is slightly longer than a grain of rice, is designed to allow people with wet AMD to go several months without [Read More]
Abicipar for Wet AMD May Extend Time Between Treatments
Allergan and Molecular Partners have announced the release of two positive clinical trials of a new treatment for wet age-related macular degeneration (wAMD). The trials, named SEQUOIA and CEDAR, demonstrated that the biological drug Abicipar is equal to Genentech’s Lucentis (ranibizumab), with the added benefit that Abicipar treatments are effective at up to 12-week dosages. [Read More]
Summary of Research and Development — 2018
Transcript of a presentation to the International Low Vision Support Group June 2018 Dan Roberts, Director Select this link for audio-visual format INTRODUCTION This is our 13th annual summary of leading research and developments occuring during the past 12 months in the fields of blindness and low vision. Sources for further information will appear beneath [Read More]